Floatz logo

LENVATINIB

Lenvatinib

Sun Yat-sen UniversitySmall moleculePhase 2Active
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
89/ 100

Competitive context

14 Active assets in the Lenvatinib cohort.

Asset / SponsorPhaseRating
Ethiodized Oil
Sun Yat-sen University
Phase 2B
Theprubicin
Sun Yat-sen University
Phase 2B
Tislelizumab
Zhejiang Cancer Hospital
Phase 2B
Pembrolizumab
National Taiwan University Hospital
Phase 2B
Cyclophosphamide
Yale University
Phase 2CCC

View all 14 →

Same molecule, other indications

LENVATINIB is also rated in:

Primary Peritoneal Cavity CancerDormant
BBB
Indicative ·
73 / 100
View asset →
Stage IIB Breast CancerDormant
BBB
Indicative ·
73 / 100
View asset →
portal vein thrombosisDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →